Sponsor or institution

Clinical trials and research at Essen Biotech

• 16Clinical trials
• 1Country

Newest trials

All recruiting trials (16)

• EBNK-001 allogeneic NK cell therapy with low-dose IL-15, with or without pembrolizumab, for advanced solid tumors

  This treatment tests an off-the-shelf NK cell product (EBNK-001) given with low-dose IL-15, either alone or with pembrolizumab, in adults with advanced or metastatic solid tumors who have exhausted standard options.

  Recruiting Phase 1/2 Essen Biotech · Beijing, Beijing Municipality · NCT07410676

• Biomarker-guided donor CAR-NK therapy targeting one or two tumor antigens for advanced solid tumors

  This treatment tries donor-derived CAR-NK cells that target one or two tumor antigens for adults with advanced solid tumors such as breast, NSCLC, colorectal, and recurrent prostate cancer.

  Recruiting Phase 1/2 Essen Biotech · Beijing, Beijing Municipality · NCT07410494

• Sequential CD146 and GPC3 CAR-T therapy for advanced ovarian cancer

  This trial will try two sequential CAR-T cell infusions—first targeting CD146 then GPC3—in adults with advanced ovarian cancer that has returned or not responded to standard treatments.

  Recruiting Phase 1/2 Essen Biotech · Beijing, Beijing Municipality · NCT07067255

• Dual-target CAR-T therapy targeting mesothelin and CLDN18.2 for advanced pancreatic cancer

  This treatment will try sequential CAR‑T cell infusions that target mesothelin and CLDN18.2 in people with unresectable or metastatic pancreatic adenocarcinoma who have received prior systemic therapy.

  Recruiting Phase 1/2 Essen Biotech · Beijing, Beijing Municipality · NCT07066995

• Sequential CD146- and HER2-targeted CAR T-cell therapy for advanced sarcoma

  This treatment will test whether giving a patient's own CAR T cells that target CD146 and HER2, one after the other, can shrink tumors in children and adults with relapsed or refractory advanced sarcoma.

  Recruiting Phase 1/2 Essen Biotech · Beijing, Beijing Municipality · NCT07066982

• Sequential CAR-T therapy targeting BCMA and GPRC5D for relapsed or refractory multiple myeloma

  This will try sequential CAR-T cell therapy against BCMA and GPRC5D in people with relapsed or refractory multiple myeloma to see if it is safe and helps control the disease.

  Recruiting Phase 1/2 Essen Biotech · Beijing, Beijing Municipality · NCT07032129

• Combining TIL Therapy and Pembrolizumab for Advanced Brain Cancer

  This study is testing a new treatment that combines a type of immune therapy using patients' own tumor cells with Pembrolizumab to see if it helps people with advanced brain cancer feel better and live longer.

  Recruiting Phase 1/2 Essen Biotech · Beijing, Beijing Municipality · NCT06640582

• Combining TIL Therapy and Pembrolizumab for Advanced Lung Cancer

  This study is testing a new treatment that combines a special type of immune cells from patients' tumors with an existing cancer drug to see if it helps people with advanced lung cancer feel better and live longer.

  Recruiting Phase 1/2 Essen Biotech · Beijing, Beijing Municipality · NCT06538012

• Combining TIL therapy and immunotherapy for advanced breast cancer

  This study is testing a new treatment that combines a special type of immune cell therapy with a drug called Pembrolizumab to see if it can help people with advanced breast cancer.

  Recruiting Phase 1/2 Essen Biotech · Beijing, Beijing Municipality · NCT06532812

• Combining TIL Therapy and Pembrolizumab for Advanced Stomach and Esophageal Cancer

  This study is testing a new treatment that combines a type of immune therapy using patients' own tumor cells with a drug called Pembrolizumab to see if it helps people with advanced stomach and esophageal cancer.

  Recruiting Phase 1/2 Essen Biotech · Beijing, Beijing Municipality · NCT06532799

• Treatment for advanced colon and rectal cancer using immune cells

  This study is testing a new treatment that uses the patient's own immune cells combined with other medications to see if it can help people with advanced colon and rectal cancer feel better and live longer.

  Recruiting Phase 1/2 Essen Biotech · Beijing, Beijing Municipality · NCT06530303

• CAR-T cell therapy targeting specific markers in autoimmune diseases

  This study is testing a new CAR-T cell therapy to see if it can help people with tough autoimmune diseases like lupus and Sjogren's syndrome feel better.

  Recruiting Phase 1/2 Essen Biotech · Beijing, Beijing Municipality · NCT06428188

• CAR-T cell therapy targeting CD5 and CD7 for T-cell leukemia and lymphoma

  This study is testing a new CAR-T cell therapy for young people with tough-to-treat T-cell leukemia and lymphoma to see if it can help them when other treatments haven't worked.

  Recruiting Phase 1/2 Essen Biotech · Beijing, Beijing Municipality · NCT06420076

• CAR-T cell therapy targeting CD33 and CD123 for treating acute myeloid leukemia

  This study is testing a new CAR-T cell therapy that targets specific markers in the blood to see if it can help people with acute myeloid leukemia who haven't responded to other treatments.

  Recruiting Phase 1/2 Essen Biotech · Beijing, Beijing Municipality · NCT06420063

• Gene therapy using BAH243 for treating sickle cell disease

  This study is testing a new gene therapy called BAH243 to see if it can safely help people with sickle cell disease feel better after receiving a stem cell transplant.

  Recruiting Phase 1/2 Essen Biotech · Beijing, Beijing Municipality · NCT06399107

• CAR T Cell Therapy for Resistant B-cell Cancers

  This study is testing a new CAR T cell therapy to see if it can safely help people with tough-to-treat B-cell cancers like leukemia and lymphoma.

  Recruiting Phase 1/2 Essen Biotech · Beijing, Beijing Municipality · NCT06213636

Quick answers

How many clinical trials run by Essen Biotech are recruiting right now?

16, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

All of them have sites in China. Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1/2: 16. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →